JMP Securities Sticks to Its Buy Rating for Sutro Biopharma (STRO)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Sutro Biopharma (STROResearch Report), with a price target of $20.00. The company’s shares closed yesterday at $6.60.

Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Sutro Biopharma, and CTI BioPharma. According to TipRanks, Benjamin has an average return of -4.6% and a 38.92% success rate on recommended stocks.

Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $25.33, which is a 283.79% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $26.00 price target.

See the top stocks recommended by analysts >>

STRO market cap is currently $290.5M and has a P/E ratio of (2.51).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.

Read More on STRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed